Atticus filed a lawsuit against FMC on Dec. 19, 2024 to confirm its expected chlorantraniliprole (CTPR) formulations and product offers do not infringe any valid patent rights owned by FMC. The lawsuit, framed as a declaratory judgment action, aims to allow Atticus to secure legal certainty and to use that certainty when it begins commercializing its CTPR portfolio.
“Atticus is committed to offering the most comprehensive, unencumbered and cost-competitive portfolio of CTPR products serving the Ag and EcoCore markets,” siad Randy Canady, CEO, Atticus. “We view CTPR as a valuable agronomic tool that has not reached its full market potential. As the price-to-agronomic value of CTPR becomes more aligned, end-users will be empowered to use CTPR in more routine agronomic rotations for better, more cost-effective insect control.”
Atticus respects the intellectual property rights of competitors such as FMC, FMC’s leadership in their defense and overall stewardship of the CTPR molecule. While Atticus attentively engaged with FMC, Atticus views the declaratory judgment action as the most effective and respectful approach to proactively clear any disputes with FMC while insulating customers from any crossfire and burdens.
